For:

• As adjunctive therapy to diet for the reduction of elevated total-C, LDLC, and Apo B in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia as monotherapy or as combination
  therapy with HMG-CoA reductase inhibitors.
• In combination with atorvastatin or simvastatin to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other non-pharmacological or lipid lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable or inadequate.
• As adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.